Articles about COVAXIN
26 Jul 2021
India to miss July vaccination target over low COVAXIN supply
India will miss its target to give out over 500 million (50 crore) coronavirus vaccine shots by the end of July, mainly because of low supplies of COVAXIN, its only indigenous jab so far.
24 Jul 2021
Bharat Biotech ends its Brazil agreement. What went wrong?
Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.
24 Jul 2021
COVID-19 vaccines for children likely by September, says AIIMS chief
India will likely have its first coronavirus vaccine for children by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).
23 Jul 2021
Bharat Biotech commits to supply 500mn COVAXIN doses to Centre
Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.
17 Jul 2021
Government to procure 66 crore doses of Covishield, COVAXIN
The Centre has placed an order to procure 66 crore doses of Covishield and COVAXIN to be supplied between August and December this year, at a revised price of Rs. 205 and Rs. 215 per dose, respectively, excluding taxes, official sources said.
28 May 2021
Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance
Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.
09 Jul 2021
Zydus vaccine for 12-18-year-olds from September, says expert panel chief
Coronavirus vaccination for children with the Zydus Cadila vaccine will start by September, said Dr. NK Arora, the chief of National Expert Group on Vaccine Administration.
03 Jul 2021
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech
COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.
01 Jul 2021
Seven EU nations, Switzerland approve India-made Covishield for 'Green Pass'
The European Union's (EU) Digital COVID Certificate framework to allow easier, restriction-free movement of vaccinated travelers within European countries—excluding India-made Covishield and COVAXIN vaccines—comes into force on Thursday.
30 Jun 2021
Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil
Hyderabad-based pharmaceutical company Bharat Biotech denied any wrongdoing on its part after Brazil suspended a $324 million contract for doses of its COVID-19 vaccine COVAXIN.
30 Jun 2021
COVAXIN effectively neutralizes the Delta variant, top US body says
Through the coronavirus pandemic, we have seen many variants emerge and cause fatal outbreaks across the globe.
23 Jun 2021
COVAXIN for children aged 2-18 by September, says AIIMS chief
India's first coronavirus vaccine for children could be ready by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).
22 Jun 2021
COVAXIN 77.8% effective; government panel reviews Phase III trial data
COVAXIN, the COVID-19 vaccine developed by Bharat Biotech, has been found 77.8% effective against the viral disease, Phase III trial data reportedly revealed.
22 Jun 2021
Bharat Biotech submits COVAXIN phase-3 trial data, review meet today
Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).
16 Jun 2021
Calf serum absent in COVAXIN, involved in development, government clarifies
COVAXIN, the indigenous COVID-19 vaccine produced by Bharat Biotech, does not contain calf serum, the Union Health Ministry clarified on Wednesday.
11 Jun 2021
FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN.
10 Jun 2021
After updating vaccine policy, Centre may renegotiate Covishield, COVAXIN prices
After India's COVID-19 vaccination policy was updated this week, the central government is likely to renegotiate prices for vaccines, a report suggested.
07 Jun 2021
AIIMS-Delhi begins screening children for COVAXIN clinical trials from today
The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN.
05 Jun 2021
Deck cleared for import of COVAXIN, Sputnik V into Brazil
Brazil has cleared the proposal to import Bharat Biotech's COVID-19 vaccine, COVAXIN, and Russia's COVID-19 vaccine Sputnik V into the South American country.
03 Jun 2021
COVAXIN trials on children aged 2-18 begin at AIIMS-Patna
The All India Institute of Medical Sciences (AIIMS) in Patna has begun the clinical trials for COVAXIN on children, reports say.
29 May 2021
Health Ministry thrashes reports about 'missing' COVAXIN doses
The Health Ministry has slammed news about unaccounted COVAXIN doses as "unfound media reports" adding that these reports are incorrect and not supported by full information on the matter.
28 May 2021
4 crore COVAXIN doses missing? Mismatch in production, availability reported
Even as India is facing an acute vaccine shortage, a report indicates that there is a mismatch in the number of doses of COVAXIN produced and the number of doses administered.
28 May 2021
Second drive-through vaccination camp inaugurated in Delhi
A two-day drive-through vaccination camp for people in the age group of 18-44 years was inaugurated by Delhi Deputy Chief Minister Manish Sisodia in Saket on Thursday, officials said.
27 May 2021
1st dose Covishield, 2nd dose COVAXIN: Vaccination blunder in UP
In a grave oversight, a group of villagers in Uttar Pradesh received two shots of two different vaccines: COVAXIN and Covishield (both two-dose vaccines).
25 May 2021
Need more information to give EUL to COVAXIN: WHO
The World Health Organization (WHO) has said that more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN.
24 May 2021
COVAXIN trials on children are expected to begin in June
Bharat Biotech, the pharmaceutical firm behind India's first indigenous COVID-19 vaccine COVAXIN, may begin trials on children in June and is expecting to receive the license in the third quarter of this year.
19 May 2021
Karnataka targets vaccinating eligible population by 2021 end
The Karnataka government has set a goal to vaccinate all eligible people in the state by November end against coronavirus.
16 May 2021
COVAXIN, Covishield effective, but produce fewer antibodies against B.1.617: Report
According to a series of early reports authored by scientists at the Indian Council of Medical Research (ICMR), COVAXIN and Covishield—vaccines deemed effective at generating an immune response against COVID-19—appear to generate only half as many antibodies against the B.1.617 variant.
13 May 2021
COVAXIN approved for Phase 2/3 trials on 2-18-year-olds
India's apex drug regulator has granted permission for conducting the Phase II/III clinical trial of Bharat Biotech's COVAXIN in the age group of 2 to 18 years, the Union Health Ministry said on Thursday. The trial will be conducted on 525 healthy volunteers.
12 May 2021
Government-owned BIBCOL to produce 2 crore COVAXIN doses every month
To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr.
12 May 2021
Bharat Biotech has refused additional COVAXIN doses to Delhi: Sisodia
Deputy Chief Minister Manish Sisodia on Wednesday said that Hyderabad-based Bharat Biotech has informed the Delhi government that it cannot provide "additional" doses of COVAXIN to the national capital.
12 May 2021
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
In a bid to extend the country's vaccination drive to include people below 18 years, an expert panel on Tuesday recommended Hyderabad-based Bharat Biotech's COVID-19 vaccine COVAXIN for phase 2/3 clinical trials on children and adolescents aged two to 18 years.
10 May 2021
COVAXIN doses unavailable for second consecutive day in Mumbai
Vaccination centers in Mumbai did not administer COVAXIN for the second straight day on Monday because of the lack of stock, leaving citizens fuming as many are due for their second dose of the vaccine.
01 May 2021
Truck laden with COVAXIN abandoned for 12 hours, driver missing
A truck carrying 2.40 lakh doses of COVAXIN worth Rs. 8 crore was left parked for nearly 12 hours after its driver went missing under mysterious circumstances in Madhya Pradesh's Narsinghpur district.
29 Apr 2021
Bharat Biotech reduces COVAXIN price to Rs. 400 for states
Hyderabad-based pharmaceutical company Bharat Biotech on Thursday reduced the price of its COVID-19 vaccine, COVAXIN, for state governments.
28 Apr 2021
Indian vaccine found effective against new COVID-19 variant: Dr. Fauci
COVAXIN, the indigenous coronavirus vaccine, has been found effective against the B.1.617 variant or the Indian "double mutant" strain, White House Chief Medical Adviser and the US' top pandemic expert, Dr. Anthony Fauci has said.
21 Apr 2021
Coronavirus: 0.04% people infected after COVAXIN shot; 0.03% after Covishield
The central government on Wednesday said that a "very small" fraction of people have tested positive for COVID-19 after being vaccinated.
21 Apr 2021
COVAXIN neutralizes double mutant strain: ICMR
Indigenously developed COVID-19 vaccine, COVAXIN, neutralizes multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said on Wednesday.
20 Apr 2021
Bharat Biotech to produce 700 million COVAXIN doses per year
To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, COVAXIN, to 700 million doses per annum, the vaccine maker said on Tuesday.
16 Apr 2021
Maharashtra institute gets nod to produce COVAXIN; Thackeray thanks Modi
The Central government has allowed the Maharashtra government-owned Haffkine Institute to manufacture COVAXIN, the coronavirus vaccine developed by Hyderabad-based Bharat Biotech and the Indian Council of Medical Research (ICMR).